Bausch + Lomb Reports Strong Q1 2026 Results, Raises Full-Year Revenue and EBITDA Guidance

summarizeSummary

Bausch + Lomb announced robust first-quarter 2026 financial results, featuring significant revenue growth and improved profitability, leading the company to raise its full-year 2026 financial guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Reported revenue increased 9% to $1.244 billion, with constant currency growth of 6%, driven by strong performance across all segments, especially Pharmaceuticals (up 14% reported).

• Significant Profitability Improvement

  GAAP net loss narrowed considerably from $212 million in Q1 2025 to $71 million in Q1 2026. Operating income turned positive at $33 million from an $83 million loss, and Adjusted EPS turned positive to $0.05 from ($0.15).

• Raised Full-Year 2026 Guidance

  The company increased its full-year revenue guidance to $5.420B - $5.520B (from $5.375B - $5.475B) and raised its Adjusted EBITDA guidance to $1.010B - $1.060B (from $1.000B - $1.050B), reflecting strong Q1 performance and a positive outlook.

auto_awesomeAnalysis

The company demonstrated strong operational execution in Q1 2026, with reported revenue increasing by 9% and a substantial reduction in GAAP net loss, alongside a shift to positive adjusted EPS. The upward revision of both revenue and Adjusted EBITDA guidance for the full year signals management's confidence in sustained performance and improved financial health. This positive update follows a 2025 annual report that showed an expanded net loss, making the Q1 turnaround and raised outlook particularly impactful for investor sentiment and the company's trajectory.